Ozempic has become the byword for semaglutide and similar drugs that cause weight loss, regardless of which brand a person is taking or why, and there have even been shortages of the drugs as people clamour to get their hands on them
This was associated with a similar level of reversion to the patients' original baselines in some markers of their cardiometabolic health a category which includes conditions such as diabetes and heart attacks
This blog will deep dive into this topic, explaining how each medication works, their overlap as GLP-1 receptor agonists, and why combining them is not recommended
Each professional brings a unique perspective and expertise, contributing to a comprehensive, patient-centred care model in which interdisciplinary collaboration is essential to address the diverse clinical, metabolic, and psychosocial challenges posed by obesity [16, 145]